All Stories

  1. The Association Between the Nonmedical use of Anabolic–Androgenic Steroids and Interpersonal Violence: A Meta-Analysis
  2. Internet sourcing and unsafe use of controlled drugs (opioids, sedatives and GABA drugs) in the UK: An in depth case study of consumer dynamics during COVID-19
  3. ‘Sustaining masculinity’: a scoping review of anabolic androgenic steroid use by older males
  4. Systems mapping to understand complexity in the association between image and performance enhancing drugs (IPEDs) and harm
  5. Anabolic androgenic steroid use population size estimation: a first stage study utilising a Delphi exercise
  6. Severity of anabolic steroid dependence, executive function, and personality traits in substance use disorder patients in Norway
  7. Generating evidence on the use of Image and performance enhancing drugs in the UK: results from a scoping review and expert consultation by the Anabolic Steroid UK network
  8. Harm reduction strategies for androgen users
  9. Human enhancement drugs: Emerging issues and responses
  10. A Scoping Review of Non-Medical and Extra-Medical Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  11. Anabolic-androgenic steroid administration increases self-reported aggression in healthy males: a systematic review and meta-analysis of experimental studies
  12. Looking Beyond the Provision of Injecting Equipment to People Who Use Anabolic Androgenic Steroids: Harm Reduction and Behavior Change Goals for UK Policy
  13. “A slippery slope”: a scoping review of the self-injection of unlicensed oils and fillers as body enhancement
  14. Internet sourcing and UK end consumer trend interest in the controlled medicines (opioids, sedatives and GABA drugs) in pre and post COVID-19 timeframes
  15. How the love of muscle can break a heart: Impact of anabolic androgenic steroids on skeletal muscle hypertrophy, metabolic and cardiovascular health
  16. Factors associated with hepatitis C and HIV testing uptake among men who inject image and performance enhancing drugs
  17. 2,4 dinitrophenol: It's not just for men
  18. Monitoring the use of drugs in bodybuilding: a novel drugs early warning system
  19. Perspectives of Frontline Professionals on Palestinian Children Living with Sibling and Parental Drug Use in the UNRWA Camps, Jordan
  20. Motives and Correlates of Anabolic-Androgenic Steroid Use With Stimulant Polypharmacy
  21. Pre-exposure Prophylaxis (PrEP) for HIV Prevention Among Men Who Have Sex with Men (MSM): A Scoping Review on PrEP Service Delivery and Programming
  22. Anabolic-Androgenic Steroid Use in the Eastern Mediterranean Region: a Scoping Review of Extant Empirical Literature
  23. The Anabolic Androgenic Steroid Treatment Gap: A National Study of Substance Use Disorder Treatment
  24. Treatments for people who use anabolic androgenic steroids: a scoping review
  25. Engaging with people who use image and performance enhancing drugs: One size does not fit all
  26. Perspectives of Frontline Professionals on Palestinian Children Living with Sibling and Parental Drug Use in the West Bank and Gaza Strip
  27. Commentary: Steroid Madness- has the dark side of anabolic-androgenic steroids (AAS) been over-stated?
  28. The modes of administration of anabolic-androgenic steroid (AAS) users: are non-injecting people who use steroids overlooked?
  29. Palestinian Children’s Experiences of Drug Abuse in the Home in the Occupied Territories of Palestine: a Scoping Review of Extant Literature
  30. Secondary distribution of injecting equipment obtained from needle and syringe programmes by people injecting image and performance enhancing drugs: England and Wales, 2012-15
  31. An evidence-based socioecological framework to understand men’s use of anabolic androgenic steroids and inform interventions in this area
  32. Identifying a typology of men who use anabolic androgenic steroids (AAS)
  33. A systematic review investigating the behaviour change strategies in interventions to prevent misuse of anabolic steroids
  34. Low levels of hepatitis C diagnosis and testing uptake among people who inject image and performance enhancing drugs in England and Wales, 2012-15
  35. Community pharmacist experiences of providing needle and syringe programmes in Ireland
  36. Adverse Effects, Health Service Engagement, and Service Satisfaction Among Anabolic Androgenic Steroid Users
  37. Anabolic steroids in the UK: an increasing issue for public health
  38. 2,4-Dinitrophenol, the inferno drug: a netnographic study of user experiences in the quest for leanness
  39. Access to needle and syringe programs by people who inject image and performance enhancing drugs
  40. A scoping review of home-produced heroin and amphetamine-type stimulant substitutes: implications for prevention, treatment, and policy
  41. Harm reduction interventions should encompass people who inject image and performance enhancing drugs
  42. Risk of HIV and Hepatitis B and C Over Time Among Men Who Inject Image and Performance Enhancing Drugs in England and Wales
  43. Polypharmacy among anabolic-androgenic steroid users: a descriptive metasynthesis
  44. Synthetic growth hormone releasers detected in seized drugs: new trends in the use of drugs for performance enhancement
  45. Anabolic steroids detected in bodybuilding dietary supplements - a significant risk to public health
  46. Environments, risk and health harms: a qualitative investigation into the illicit use of anabolic steroids among people using harm reduction services in the UK
  47. The composition of anabolic steroids from the illicit market is largely unknown: implications for clinical case reports
  48. Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet
  49. Injection site infections and injuries in men who inject image- and performance-enhancing drugs: prevalence, risks factors, and healthcare seeking
  50. Online marketing of synthetic peptide hormones: poor manufacturing, user safety, and challenges to public health
  51. Views and experiences of hepatitis C testing and diagnosis among people who inject drugs: Systematic review of qualitative research
  52. Is the breast cancer drug tamoxifen being sold as a bodybuilding dietary supplement?
  53. Variability and dilemmas in harm reduction for anabolic steroid users in the UK: a multi-area interview study
  54. Effectiveness of interventions to increase hepatitis C testing uptake among high-risk groups: a systematic review
  55. Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: a cross-sectional study
  56. Epidemiology of Use of Novel Psychoactive Substances
  57. Drogas potenciadoras para la búsqueda de la perfección
  58. Drogas potenciadoras para la búsqueda de la perfección
  59. Social, policy, and public health perspectives on new psychoactive substances
  60. Should "legal highs" be regulated as medicinal products?
  61. Next generation challenges: An overview of harm reduction 2010, IHRA's 21st conference
  62. Adulterants in illicit drugs: a review of empirical evidence
  63. Meeting the health needs of problematic drug users through community pharmacy: A qualitative study
  64. Older and sicker: Changing mortality of drug users in treatment in the North West of England
  65. Optimal provision of needle and syringe programmes for injecting drug users: A systematic review
  66. Injecting human growth hormone as a performance-enhancing drug—perspectives from the United Kingdom
  67. Integrating Drug-Related Monitoring Systems—An Intelligence Led Approach
  68. Elephant in the room? The methodological implications for public health research of performance-enhancing drugs derived from the illicit market
  69. Use of melanotan I and II in the general population
  70. The dire consequences of doping?
  71. Diversion and abuse of methylphenidate in light of new guidance
  72. The Involvement of Drugs and Alcohol in Drug-Facilitated Sexual Assault
  73. Problematic drug use, ageing and older people: trends in the age of drug users in northwest England
  74. The impact of citrate introduction at UK syringe exchange programmes: a retrospective cohort study in Cheshire and Merseyside, UK
  75. The role of substance use in non‐drug related deaths: a cross‐sectional study of drug treatment clients in the North West of England
  76. DRINK DETECTIVE: COMMENTS ON THE MANUFACTURER'S RESPONSE
  77. The ability of two commercially available quick test kits to detect drug-facilitated sexual assault drugs in beverages
  78. Trends in drop out, drug free discharge and rates of re-presentation: a retrospective cohort study of drug treatment clients in the North West of England
  79. Crack-cocaine injection: A retrospective analysis of clients in Merseyside specialist drug treatment agencies
  80. Effects of nightlife activity on health
  81. Effects of nightlife activity on health
  82. A potent cocktail
  83. New challenges for agency based syringe exchange schemes: analysis of 11 years of data (1991–2001) in Merseyside and Cheshire, United Kingdom
  84. Predictors of hepatitis B and C infection in injecting drug users both in and out of drug treatment
  85. Water usage reduction in a semiconductor fabricator